as 04-18-2025 1:44pm EST
2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The company operates in a single segment, focusing on researching, developing and commercializing potentially transformative treatments for cancer.
Founded: | 2021 | Country: | United States |
Employees: | N/A | City: | CAMBRIDGE |
Market Cap: | 258.9M | IPO Year: | N/A |
Target Price: | $6.50 | AVG Volume (30 days): | 1.1M |
Analyst Decision: | Buy | Number of Analysts: | 4 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -1.10 | EPS Growth: | N/A |
52 Week Low/High: | $2.29 - $5.30 | Next Earning Date: | 05-07-2025 |
Revenue: | $37,862,000 | Revenue Growth: | -62.28% |
Revenue Growth (this year): | 84.48% | Revenue Growth (next year): | 9.69% |
Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
Snow Jessica | TSVT | Chief Operating Officer | Mar 17 '25 | Sell | $4.95 | 2,298 | $11,363.61 | 254,193 | |
Baird William D III | TSVT | President and CEO | Mar 17 '25 | Sell | $4.95 | 5,092 | $25,179.94 | 1,121,034 | |
Eatwell Victoria | TSVT | Chief Financial Officer | Mar 17 '25 | Sell | $4.95 | 2,592 | $12,817.44 | 444,387 | |
Kynam Global Healthcare Master Fund, LP | TSVT | 10% Owner | Mar 11 '25 | Sell | $4.93 | 16,238,047 | $80,053,571.71 | 0 |
TSVT Breaking Stock News: Dive into TSVT Ticker-Specific Updates for Smart Investing
Simply Wall St.
9 days ago
Simply Wall St.
18 days ago
Business Wire
25 days ago
Simply Wall St.
a month ago
Business Wire
a month ago
Business Wire
2 months ago
Simply Wall St.
2 months ago
Business Wire
2 months ago
The information presented on this page, "TSVT 2seventy bio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.